Skip to main content
THERAGEN ETEX CO.,LTD. logo

THERAGEN ETEX CO.,LTD. — Investor Relations & Filings

Ticker · 066700 ISIN · KR7066700006 KO Manufacturing
Open in API
Filings indexed 192 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country KR South Korea
Listing KO 066700

About THERAGEN ETEX CO.,LTD.

http://www.theragenetex.com/

THERAGEN ETEX CO.,LTD. is a biotechnology and pharmaceutical group focused on genome-based personalized and precision medicine. The company integrates advanced genomic analysis with pharmaceutical development and manufacturing. Its genomics division provides comprehensive genetic analysis services, leveraging pioneering achievements such as creating the world's first female and tiger genome maps and commercializing Asia's first individual genome analysis service. The pharmaceutical division develops and supplies medicines from its international GMP-certified facilities. The R&D pipeline focuses on incrementally modified drugs, orphan drugs, and novel anticancer therapies, including its proprietary drug candidate, Vactosertib, which is in clinical trials for various cancers.

Recent filings

Filing Released Lang Actions
소속부변경
Regulatory Filings
2026-04-30 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory announcement disclosing the appointment, reappointment, or dismissal of an outside director (“사외이사 신규선임ㆍ재선임”). It provides details on the change in board composition and director biography. This matches the definition for Board/Management Information (MANG).
2026-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled “정기주주총회결과” (Regular General Meeting of Shareholders Results) and provides detailed voting outcomes for each agenda item at the AGM, including vote percentages and resolutions passed. It is not a proxy solicitation, a report publication announcement, or the full annual report itself, but rather the official declaration of voting results. Thus it should be classified as a Declaration of Voting Results (DVA).
2026-03-27 Korean
[첨부정정]사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a full standalone auditor’s report (“감사보고서”) on the company’s financial statements for the year ended December 31, 2025, including the independent auditor’s opinion, detailed financial statements (balance sheet, income statement, cash flow, equity changes), notes, and internal control report. This is not merely an announcement or summary but the complete audit report and accompanying statements, matching the definition of Audit Report / Information (AR). FY 2025
2026-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from a Korean company. It provides key financial data, audit opinions, and financial statements for the fiscal year. While it contains financial data, it is a standard regulatory disclosure announcement (DART filing) in Korea that serves as a formal notification of the audit report's submission to the regulator, rather than the full 10-K annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2025
2026-03-19 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is titled '사업보고서' (Business Report) for the 36th fiscal year (2025), which is the standard terminology for an Annual Report in South Korea. It contains comprehensive company information, including business overview, financial data, management details, and shareholding information. It is a full-length report (over 500,000 characters) rather than an announcement or summary, fitting the definition of a 10-K (Annual Report). FY 2025
2026-03-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.